Pharvaris CCO sells 26,090 shares in preset plan

Available on EDGAR 09/16/2026 - 02:07 PM EDT Accepted by SEC EDGAR 09/16/2026 - 02:07 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Pharvaris N.V. (PHVS) reported that Chief Commercial Officer Wim Souverijns exercised options and sold shares in mid-September 2026 under a Rule 10b5-1 trading plan. On September 14, 2026, he exercised options for 20,000 shares at $17.43 per share and immediately sold 20,000 shares in a cashless exercise at a weighted average price of $39.31. On September 15, 2026, he separately sold 6,090 shares at $38.99 per share, also under a Rule 10b5-1 plan. Following the option exercise, 95,000 options from that grant remained outstanding.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 4 txns

Insider Souverijns Wim

Role Chief Commercial Officer

Sold 26,090 shs ($1.02M)

Approx. gross sale proceeds $1.02M

Approx. exercise cost $349K

Type	Security	Shares	Price	Value
Sale	Common Stock F3	6,090	$38.99	$237K
Exercise	Stock Option (Right to Buy) F4	20,000	$0.00	$0.00
Exercise	Common Stock F1	20,000	$17.43	$349K
Sale	Common Stock F1, F2	20,000	$39.3063	$786K

Holdings After Transaction: Stock Option (Right to Buy) — 95,000 contracts (Direct); Common Stock — 39,021 shares (Direct)

Footnotes (4)

1. F1. This is a scheduled exercise and sale from 10b5-1 trading plan.
2. F2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $39.00 to $39.63. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
3. F3. This is a scheduled sale from 10b5-1 trading plan.
4. F4. 25% of the option vested on July 1, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

Key Figures

Shares sold September 14, 2026: 20,000 shares Weighted average sale price September 14, 2026: $39.31 per share Shares sold September 15, 2026: 6,090 shares +5 more

8 metrics

Shares sold September 14, 2026 20,000 shares Common stock sold in connection with a cashless option exercise under a trading plan

Weighted average sale price September 14, 2026 $39.31 per share Sale prices ranged from $39.00 to $39.63 per share

Shares sold September 15, 2026 6,090 shares Common stock sale in open-market or private transactions under a trading plan

Sale price September 15, 2026 $38.99 per share Per-share sale price for 6,090 common shares

Options exercised 20,000 options Stock options exercised into common shares on September 14, 2026

Option exercise price $17.43 per share Exercise price for 20,000 options converted into common stock

Remaining options from grant 95,000 options Outstanding after the September 14, 2026 option exercise, expiring July 1, 2031

Option expiration date July 1, 2031 Expiration for the remaining options under the reported grant

Key Terms

Rule 10b5-1 trading plan, cashless exercise transaction, weighted average sale price, vesting

4 terms

Rule 10b5-1 trading plan regulatory

"The shares were sold in connection with the exercise of stock options in a cashless exercise transaction pursuant to a Rule 10b5-1 trading plan."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

cashless exercise transaction financial

"The shares were sold in connection with the exercise of stock options in a cashless exercise transaction."

weighted average sale price financial

"The reported price represents a weighted average sale price for shares sold in multiple transactions."

vesting financial

"Twenty-five percent of the option vested on July 1, 2022 with remaining shares vesting in monthly installments thereafter."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did PHVS report for Wim Souverijns in September 2026?

Pharvaris N.V. reported that Chief Commercial Officer Wim Souverijns exercised options for 20,000 shares on September 14, 2026 and sold 26,090 shares of common stock over September 14–15, 2026, in transactions made pursuant to a Rule 10b5-1 trading plan.

How many PHVS shares did Wim Souverijns sell and at what prices?

He sold 20,000 shares of Pharvaris N.V. common stock on September 14, 2026 at a weighted average price of $39.31 per share, and 6,090 shares on September 15, 2026 at $38.99 per share, all in open-market or private transactions under a trading plan.

What options did Wim Souverijns exercise in PHVS on September 14, 2026?

On September 14, 2026, Wim Souverijns exercised stock options covering 20,000 shares of Pharvaris N.V. common stock at an exercise price of $17.43 per share. These options were part of a grant that vests over time according to a stated vesting schedule.

How many PHVS options remain after the reported exercise by Wim Souverijns?

After the reported September 14, 2026 option exercise, the filing shows that 95,000 options from the referenced grant remain outstanding for Wim Souverijns, with an expiration date of July 1, 2031.

Were Wim Souverijns’ PHVS share sales made under a Rule 10b5-1 plan?

Yes. The filing states that the September 14, 2026 cashless exercise and related sale, and the September 15, 2026 sale of 6,090 shares, were scheduled transactions made pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Souverijns Wim

(Last) (First) (Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/14/2026		M(1)		20,000	A	$17.43	65,111	D
Common Stock	09/14/2026		S(1)		20,000	D	$39.3063(2)	45,111	D
Common Stock	09/15/2026		S(3)		6,090	D	$38.99	39,021	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$17.43	09/14/2026		M			20,000	(4)	07/01/2031	Common Stock	20,000	$0	95,000	D

Explanation of Responses:

1. This is a scheduled exercise and sale from 10b5-1 trading plan.

2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $39.00 to $39.63. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

3. This is a scheduled sale from 10b5-1 trading plan.

4. 25% of the option vested on July 1, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

	/s/ Marnus Nel, Attorney-in-Fact for Wim Souverjins	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)